About Pieris Pharmaceuticals (NASDAQ:PIRS)
Pieris Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company's pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids. It is focused on developing three drug candidates, which include PRS-080, PRS-060 and PRS-300 series. Its PRS-080 is an Anticalin drug candidate targeting hepcidin. The Company's second Anticalin drug candidate, PRS-060, binds to the IL-4 receptor alpha-chain (IL-4RA), thereby inhibiting the actions of IL-4 and IL-13, two cytokines known to be mediators in the inflammatory cascade that causes asthma and other inflammatory diseases. PRS-343 is an Anticalin-based drug candidate.
Industry, Sector and Symbol
Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:PIRS
CUSIPN/A
Phone857-246-8998
Debt
Debt-to-Equity RatioN/A
Current Ratio1.96%
Quick Ratio1.96%
Price-To-Earnings
Trailing P/E Ratio-16.40
Forward P/E Ratio-12.38
P/E GrowthN/A
Sales & Book Value
Annual Sales$25.27 million
Price / Sales13.98
Cash FlowN/A
Price / CashN/A
Book Value$0.26 per share
Price / Book25.23
Profitability
EPS (Most Recent Fiscal Year)($0.40)
Net Income$-17,640,000.00
Net Margins-69.82%
Return on Equity-162.54%
Return on Assets-19.05%
Miscellaneous
Employees68
Outstanding Shares53,850,000
Pieris Pharmaceuticals (NASDAQ:PIRS) Frequently Asked Questions
What is Pieris Pharmaceuticals' stock symbol?
Pieris Pharmaceuticals trades on the NASDAQ under the ticker symbol "PIRS."
How were Pieris Pharmaceuticals' earnings last quarter?
Pieris Pharmaceuticals Inc (NASDAQ:PIRS) posted its quarterly earnings data on Friday, March, 9th. The biotechnology company reported $0.17 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.04) by $0.21. The biotechnology company had revenue of $18.15 million for the quarter, compared to analysts' expectations of $7.63 million. Pieris Pharmaceuticals had a negative net margin of 69.82% and a negative return on equity of 162.54%. View Pieris Pharmaceuticals' Earnings History.
What price target have analysts set for PIRS?
5 analysts have issued 1-year price objectives for Pieris Pharmaceuticals' stock. Their forecasts range from $9.00 to $13.00. On average, they anticipate Pieris Pharmaceuticals' stock price to reach $11.50 in the next year. View Analyst Ratings for Pieris Pharmaceuticals.
Are investors shorting Pieris Pharmaceuticals?
Pieris Pharmaceuticals saw a increase in short interest in the month of March. As of March 15th, there was short interest totalling 2,774,289 shares, an increase of 58.2% from the February 28th total of 1,753,784 shares. Based on an average daily volume of 1,111,459 shares, the days-to-cover ratio is currently 2.5 days. Currently, 5.5% of the shares of the stock are sold short.
Who are some of Pieris Pharmaceuticals' key competitors?
Some companies that are related to Pieris Pharmaceuticals include ANI Pharmaceuticals (ANIP), BeyondSpring (BYSI), STAAR Surgical (STAA), Rocket Pharmaceuticals (RCKT), Omeros (OMER), Triple-S Management (GTS), Anika Therapeutics (ANIK), New England Nuclear (LNTH), AMAG Pharmaceuticals (AMAG), RadNet (RDNT), Novavax (NVAX), Endocyte (ECYT), Hanger (HNGR), Mesa Laboratories (MLAB), Jounce Therapeutics (JNCE), Tactile Systems Technology (TCMD), Lannett (LCI) and Addus HomeCare (ADUS).
Who are Pieris Pharmaceuticals' key executives?
Pieris Pharmaceuticals' management team includes the folowing people:
- James A. Geraghty, Chairman of the Board (Age 62)
- Stephen S. Yoder, President, Chief Executive Officer, Director (Age 39)
- Lance E. Thibault, Acting Chief Financial Officer (Age 50)
- Claude Knopf, Senior Vice President, Chief Business Officer
- Louis A. Matis M.D., Senior Vice President and Chief Development Officer (Age 54)
- Julian Adams, Director (Age 61)
- Jean-Pierre Bizzari M.D., Director (Age 62)
- Christopher P. Kiritsy, Director (Age 49)
- Steven Prelack, Independent Director (Age 57)
- Michael Richman, Independent Director (Age 54)
Has Pieris Pharmaceuticals been receiving favorable news coverage?
Media headlines about PIRS stock have trended somewhat positive recently, according to Accern. Accern scores the sentiment of media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Pieris Pharmaceuticals earned a coverage optimism score of 0.10 on Accern's scale. They also gave news stories about the biotechnology company an impact score of 46.68 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near future.
How do I buy shares of Pieris Pharmaceuticals?
Shares of PIRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Pieris Pharmaceuticals' stock price today?
One share of PIRS stock can currently be purchased for approximately $6.56.
How big of a company is Pieris Pharmaceuticals?
Pieris Pharmaceuticals has a market capitalization of $353.29 million and generates $25.27 million in revenue each year. The biotechnology company earns $-17,640,000.00 in net income (profit) each year or ($0.40) on an earnings per share basis. Pieris Pharmaceuticals employs 68 workers across the globe.
How can I contact Pieris Pharmaceuticals?
Pieris Pharmaceuticals' mailing address is 255 State Street 9th Floor, Boston MA, 02109. The biotechnology company can be reached via phone at 857-246-8998 or via email at [email protected]
MarketBeat Community Rating for Pieris Pharmaceuticals (PIRS)
MarketBeat's community ratings are surveys of what our community members think about Pieris Pharmaceuticals and other stocks. Vote "Outperform" if you believe PIRS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PIRS will underperform the S&P 500 over the long term. You may vote once every thirty days.
Pieris Pharmaceuticals (NASDAQ:PIRS) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
5 Wall Street analysts have issued ratings and price targets for Pieris Pharmaceuticals in the last 12 months. Their average twelve-month price target is $11.50, suggesting that the stock has a possible upside of 75.30%. The high price target for PIRS is $13.00 and the low price target for PIRS is $9.00. There are currently 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $11.50 | $11.00 | $10.00 | $9.00 |
| Price Target Upside: | 75.30% upside | 54.93% upside | 44.51% upside | 70.45% upside |
Pieris Pharmaceuticals (NASDAQ:PIRS) Consensus Price Target History
Pieris Pharmaceuticals (NASDAQ:PIRS) Analyst Ratings History
Show:
(Data available from 4/22/2016 forward)
Pieris Pharmaceuticals (NASDAQ:PIRS) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Pieris Pharmaceuticals (NASDAQ PIRS) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 4.05%
Institutional Ownership Percentage: 43.99%
Pieris Pharmaceuticals (NASDAQ PIRS) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 2/13/2018 | Orbimed Advisors Llc | Major Shareholder | Sell | 7,897 | $8.98 | $70,915.06 | |  |
| 1/3/2018 | Orbimed Advisors Llc | Major Shareholder | Sell | 1,709,620 | $7.35 | $12,565,707.00 | | |
| 12/18/2017 | Orbimed Advisors Llc | Major Shareholder | Sell | 147,635 | $5.70 | $841,519.50 | | |
| 8/17/2017 | Allan Reine | Insider | Buy | 65,000 | $4.82 | $313,300.00 | 45,000 | |
| 8/17/2017 | James A Geraghty | Director | Buy | 10,000 | $4.82 | $48,200.00 | 10,000 | |
| 6/14/2016 | Louis Matis | SVP | Buy | 10,000 | $1.70 | $17,000.00 | 2,085 | |
| 6/13/2016 | Darlene M Deptula-Hicks | CFO | Buy | 5,000 | $1.66 | $8,300.00 | 5,000 | |
| 6/13/2016 | Stephen S Yoder | CEO | Buy | 6,000 | $1.68 | $10,080.00 | 6,000 | |
(Data available from 1/1/2013 forward)
Pieris Pharmaceuticals (NASDAQ PIRS) News Headlines
| Source: |
|
Pieris Pharmaceuticals (NASDAQ:PIRS) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Pieris Pharmaceuticals (NASDAQ:PIRS) Income Statement, Balance Sheet and Cash Flow Statement
Pieris Pharmaceuticals (NASDAQ PIRS) Stock Chart for Sunday, April, 22, 2018
Loading chart…
